Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.13%
#3 CoW Protocol CoW Protocol +37.72%
#4 Glidr Glidr +36.87%
#5 RedStone RedStone +30.25%
#6 Humanity Humanity +24.45%
#7 Codatta Codatta +21.34%
#8 The Black Bull The Black Bull +19.65%
#9 Walrus Walrus +19.14%
#10 Tutorial Tutorial +19.10%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
株式のランク #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
株価
$1.73
最終同期: 2025-06-17
時価総額
$2.55M
変化（1日）
-0.29%
変化（1年）
0.00%
国
US
取引 Eiger BioPharmaceuticals, Inc. (EIGR)

カテゴリー

Healthcare
Eiger BioPharmaceuticals, Inc.（EIGR）の収益
Aug 2026 時点の収益 TTM: 0
Eiger BioPharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Eiger BioPharmaceuticals, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE